GO306 / GeneSail Biotech - LARVOL DELTA

The investigator-initiated trial (IIT) of GO306 injection, a recombinant oncolytic vaccinia virus, in patients with advanced soft tissue sarcomas. (ASCO 2026) - P=N/A | "Intratumoral GO306 showed favorable safety profile and manageable TRAEs in pretreated advanced STS. Preliminary efficacy support phase I/II expansion and combination studies with other immunotherapies or targeted therapies. Clinical Trial Registration Number: ChiCTR2400088508."

Clinical • Metastases • Oncolytic virus • Endocrine Disorders • Infectious Disease • Respiratory Diseases • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • TGFB1

A Clinical Study of GO306 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=32 | Recruiting | Sponsor: GeneSail Biotech (Shanghai) Co., Ltd.

New P1 trial • Tumor mutational burden • Oncology • Solid Tumor • PD-L1

To evaluate the safety, tolerability and preliminary efficacy of GO306 recombinant oncolytic vaccinia virus injection in patients with advanced refractory solid tumors (ChiCTR) - P1 | N=32 | Not yet recruiting | Sponsor: The first affiliated hospital of anhui medical university; The first affiliated hospital of anhui medical university

New P1 trial • Breast Cancer • Colorectal Cancer • Gastrointestinal Cancer • Ovarian Cancer • Renal Cell Carcinoma • Small Cell Lung Cancer • Solid Tumor • Triple Negative Breast Cancer • BRCA • MSI